In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dharmacon Inc.

Division of Thermo Fisher Scientific Inc.
www.dharmacon.com

Latest From Dharmacon Inc.

Appointments: Amgen, Sirnaomics, Pandion, Purdue, Cardurion, OncoSec Make Senior Hires

Senior executives are to depart Gilead Sciences, Bristol-Myers Squibb and Amgen, while C-suite and board hires have been reported at Sirnaomics, Pandion, Purdue Pharma, Cardurion and OncoSec.

Appointments Commercial

Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology

The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
BioPharmaceutical Strategy

Deal Statistics Quarterly, Q1 2004

Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.
BioPharmaceutical Medical Device

Acuity Pharmaceuticals Inc.

Acuity Pharmaceuticals is developing VEGF-directed RNAi-based therapeutics for ophthalmic diseases, including age-related wet macular degeneration and diabetic retinopathy.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Thermo Fisher Scientific Inc.
  • Senior Management
  • Timothy Hoogheem, EVP, Fin. & CFO
    Michael Deines, VP, Mktg.
    Stephen A Scaringe, PhD, CSO
  • Contact Info
  • Dharmacon Inc.
    Phone: (303) 604-9499
    1376 Miners Dr. #101
    Lafayette, CO 80026
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register